Lane B. Benes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lane B. Benes has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Michael H. Davidson
The University of Chicago Pritzker School of Medicine
2 shared publications Atman P. Shah
University of Chicago, Chicago, IL, 60637, USA
1 shared publicationCevher Ozcan
University of Chicago, Chicago, IL, 60637, USA
1 shared publication- Daniel J. Brandt
Department of Epidemiology, The University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, MI, 48109, USA
1 shared publication - Eric J. Brandt
Institute for Healthcare Policy and Innovation University of Michigan Ann Arbor Michigan USA
1 shared publication Jonathan R. Rosenberg
University of Chicago, Chicago, IL, 60637, USA
1 shared publication
Latest Publications
- 1 February 2020
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 21 (2) , 200-204
The Role of Genetics in Cardiovascular Risk Reduction: Findings From a Single Lipid Clinic and Review of the Literature
- 1 February 2020
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 21 (2) , 200-204
The Role of Genetics in Cardiovascular Risk Reduction: Findings From a Single Lipid Clinic and Review of the Literature
- 17 October 2018
- Published by Springer Nature in Current Cardiology Reports
- Vol. 20 (12) , 1-7
How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention
Purpose of the Review To summarize advances in genomic medicine and anticipated future directions to improve cardiovascular risk reduction. Recent Findings Mendelian randomization and genome-wide association studies have given significant insights into the role of genetics in dyslipidemia and cardiovascular disease (CVD), with over 160 gene loci found to be associated with coronary artery disease to date. This has enabled the creation of genetic risk scores that have demonstrated improved risk prediction when added to clinical markers of CVD risk. Summary Incorporation of genomic data into clinical patient care is on the horizon. Genomic medicine is expected to offer improved risk assessment, determination of targeted treatment strategies, and improved detection of lipid disorders causal to CVD development.
- 17 October 2018
- Published by Springer Nature in Current Cardiology Reports
- Vol. 20 (12) , 1-7
How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention
Purpose of the Review To summarize advances in genomic medicine and anticipated future directions to improve cardiovascular risk reduction. Recent Findings Mendelian randomization and genome-wide association studies have given significant insights into the role of genetics in dyslipidemia and cardiovascular disease (CVD), with over 160 gene loci found to be associated with coronary artery disease to date. This has enabled the creation of genetic risk scores that have demonstrated improved risk prediction when added to clinical markers of CVD risk. Summary Incorporation of genomic data into clinical patient care is on the horizon. Genomic medicine is expected to offer improved risk assessment, determination of targeted treatment strategies, and improved detection of lipid disorders causal to CVD development.
- 11 March 2017
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 91 (8) , 652-1114
Intravascular ultrasound to assess for baffle stenosis after Mustard procedure
- 11 March 2017
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 91 (8) , 652-1114
Intravascular ultrasound to assess for baffle stenosis after Mustard procedure